Enlivex Therapeutics (ENLV) said Wednesday it received a notice of allowance from the Japanese Patent Office for a patent application focused on the use of Allocetra in osteoarthritis patients.
The patent, which will secure the company's intellectual property rights in Japan until 2040, is expected to be officially issued by the end of Q2 2025, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.